<DOC>
	<DOCNO>NCT02806752</DOCNO>
	<brief_summary>The purpose study evaluate effect safety ranibizumab therapy combine TA versus ranibizumab monotherapy patient polypoidal choroidal vasculopathy ( PCV ) . Furthermore , pharmacogenetics effect inflammatory relate gene polymorphism response treatment . To confirm role inflammatory factor pathogenesis advance PCV .</brief_summary>
	<brief_title>Intravitreal Ranibizumab TA Combination Therapy vs. Ranibizumab Monotherapy Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>Polypoidal choroidal vasculopathy ( PCV ) , vascular disease choroid , appear predominant subtype exudative `` wet '' AMD Asian population , contrast choroidal neovascularization secondary AMD ( CNV-AMD ) Western population . There distinct difference pathophysiological , clinical epidemiological factor two subtypes , although also share common risk factor . In contrast CNV-AMD , PCV seem respond well anti-VEGF treatment . The optimal treatment option PCV remain elusive , study show good short-term visual outcome poorer longer-term outcome current treatment strategy . Therefore , understand pathogenesis PCV , develop novel effective treatment strategy prevent PCV-related vision loss significant unmet need . The purpose study assess effect safety ranibizumab therapy combine TA versus ranibizumab monotherapy patient PCV . Second , pharmacogenetics effect inflammatory relate gene polymorphism response treatment PCV explore . To confirm role inflammatory factor pathogenesis advance PCV , important determine level inflammatory factor anterior chamber aqueous humor PCV patient , compare aqueous humor acquire age-matched age-related cataract patient undergoing phacoemulsification .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>bestcorrected visual acuity ( BCVA ) letter score 73 24 use Early Treatment Diabetic Retinopathy Study chart start distance 4 ( 20/40 20/320 Snellen equivalent ) ; great lineardimensionof lesion &lt; 5400 um ( 9 Macular Photocoagulation Study disk area ) , assess ICGA ; Crossreading different center conﬁrmed diagnosis PCV , , presence early subretinal focal ICGA hyperﬂuorescence ( appear within ﬁrst 6 minute injection indocyanine green ) addition , least one follow angiographic clinical criterion : ( ) association BVN , ( ii ) presence pulsatile polyp , ( iii ) nodular appearance view stereoscopically , ( iv ) presence hypoﬂuorescent halo ( ﬁrst 6 minute ) ,7 ( v ) orange subretinal nodule stereoscopic color fundus photograph ( polyp correspond ICGA lesion ) , ( vi ) association massive submacular hemorrhage ( deﬁned size hemorrhage least 4 disk area ) . receive treatment previously verteporﬁn PDT , focal laser photocoagulation , transpupillary thermotherapy , pneumatic displacement subretinal blood , investigational treatment ; history angioid streak , presume ocular histoplasmosis syndrome , pathologic myopia ; experience RPE tear , retinal detachment , macular hole , uncontrolled glaucoma ; undergone intraocular surgery ( except uncomplicated cataract extraction intraocular lens implantation within 60 day screen visit )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
</DOC>